Bioxcel therapeutics reports third quarter 2022 financial results and recent operational highlights

Igalmi™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major u.s. geographies

BTAI Ratings Summary

BTAI Quant Ranking